Business Description
Hansoh Pharmaceutical Group Co Ltd
ISIN : KYG549581067
Compare
Compare
Traded in other countries / regions
03692.Hong Kong3KY.GermanyHNSPF.USA IPO Date
2019-06-14Description
Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 196.35 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-EBITDA | 0.02 | |||||
| Interest Coverage | 107.57 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 10 | |||||
| Beneish M-Score | -2.48 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 1.6 | |||||
| 3-Year EBITDA Growth Rate | 4.3 | |||||
| 3-Year EPS without NRI Growth Rate | 2 | |||||
| 3-Year FCF Growth Rate | 37.6 | |||||
| 3-Year Book Growth Rate | 10 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 9.85 | |||||
| Future 3-5Y Total Revenue Growth Rate | 9.26 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 34.53 | |||||
| 9-Day RSI | 39.46 | |||||
| 14-Day RSI | 42.27 | |||||
| 6-1 Month Momentum % | 13.48 | |||||
| 12-1 Month Momentum % | 31.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.98 | |||||
| Quick Ratio | 7.81 | |||||
| Cash Ratio | 6.85 | |||||
| Days Inventory | 201.68 | |||||
| Days Sales Outstanding | 95.1 | |||||
| Days Payable | 72.39 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.93 | |||||
| Dividend Payout Ratio | 0.27 | |||||
| Forward Dividend Yield % | 1.93 | |||||
| 5-Year Yield-on-Cost % | 1.84 | |||||
| Shareholder Yield % | 4.27 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 91.12 | |||||
| Operating Margin % | 36.59 | |||||
| Net Margin % | 38.94 | |||||
| FCF Margin % | 34.18 | |||||
| ROE % | 18.1 | |||||
| ROA % | 14.57 | |||||
| ROIC % | 43.49 | |||||
| ROC (Joel Greenblatt) % | 130.15 | |||||
| ROCE % | 20.55 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 22.11 | |||||
| Forward PE Ratio | 26.22 | |||||
| PE Ratio without NRI | 22.64 | |||||
| Price-to-Owner-Earnings | 29.26 | |||||
| PEG Ratio | 3.48 | |||||
| PS Ratio | 8.35 | |||||
| PB Ratio | 3.6 | |||||
| Price-to-Tangible-Book | 3.62 | |||||
| Price-to-Free-Cash-Flow | 24.39 | |||||
| Price-to-Operating-Cash-Flow | 21.68 | |||||
| EV-to-EBIT | 13.75 | |||||
| EV-to-Forward-EBIT | 18.82 | |||||
| EV-to-EBITDA | 12.81 | |||||
| EV-to-Revenue | 6.16 | |||||
| EV-to-Forward-Revenue | 5.67 | |||||
| EV-to-FCF | 18.18 | |||||
| Price-to-Projected-FCF | 2.29 | |||||
| Price-to-Peter-Lynch-Fair-Value | 5.11 | |||||
| Price-to-Graham-Number | 1.91 | |||||
| Price-to-Net-Current-Asset-Value | 4.24 | |||||
| Price-to-Net-Cash | 5.08 | |||||
| Earnings Yield (Greenblatt) % | 7.27 | |||||
| FCF Yield % | 4.15 | |||||
| Forward Rate of Return (Yacktman) % | 8.8 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hansoh Pharmaceutical Group Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 13,120.511 | ||
| EPS (TTM) (HK$) | 0.823 | ||
| Beta | 0.82 | ||
| Volatility % | 44.55 | ||
| 14-Day RSI | 42.27 | ||
| 14-Day ATR (HK$) | 0.712681 | ||
| 20-Day SMA (HK$) | 18.579 | ||
| 12-1 Month Momentum % | 31.53 | ||
| 52-Week Range (HK$) | 11.18 - 22.8 | ||
| Shares Outstanding (Mil) | 5,934.34 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hansoh Pharmaceutical Group Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hansoh Pharmaceutical Group Co Ltd Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Hansoh Pharmaceutical Group Co Ltd Frequently Asked Questions
What is Hansoh Pharmaceutical Group Co Ltd(HKSE:03692)'s stock price today?
The current price of HKSE:03692 is HK$18.20. The 52 week high of HKSE:03692 is HK$22.80 and 52 week low is HK$11.18.
When is next earnings date of Hansoh Pharmaceutical Group Co Ltd(HKSE:03692)?
The next earnings date of Hansoh Pharmaceutical Group Co Ltd(HKSE:03692) is .
Does Hansoh Pharmaceutical Group Co Ltd(HKSE:03692) pay dividends? If so, how much?
The Dividend Yield %  of Hansoh Pharmaceutical Group Co Ltd(HKSE:03692) is 1.93% (As of Today), Highest Dividend Payout Ratio of Hansoh Pharmaceutical Group Co Ltd(HKSE:03692) was 0.29. The lowest was 0.14. And the median was 0.22. The  Forward Dividend Yield % of Hansoh Pharmaceutical Group Co Ltd(HKSE:03692) is 1.93%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers